Dr Reddys Laboratories Stock Performance
| RDY Stock | USD 15.37 0.25 1.65% |
The firm owns a Beta (Systematic Risk) of 0.61, which means possible diversification benefits within a given portfolio. As returns on the market increase, Dr Reddys' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dr Reddys is expected to be smaller as well. At this point, Dr Reddys Laboratories has a negative expected return of -0.0435%. Please make sure to confirm Dr Reddys' total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if Dr Reddys Laboratories performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Dr Reddys Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Dr Reddys is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.65 | Five Day Return 5.2 | Year To Date Return 8.47 | Ten Year Return 53.24 | All Time Return 1.4 K |
Forward Dividend Yield 0.0062 | Payout Ratio 0.0023 | Last Split Factor 5:1 | Forward Dividend Rate 0.1 | Dividend Date 2024-08-12 |
1 | Tri Chemical Laboratories Dividend Will Be 30.00 | 12/02/2024 |
2 | Joinn LaboratoriesCo.,Ltd.s top owners are individual investors with 42 percent stake, while 40 percent is held by insiders | 12/06/2024 |
3 | Certified Laboratories Approved as Amazon TIC for Ophthalmic and Skin-Lightening Products | 12/11/2024 |
4 | Dolby Laboratories, Inc. Sees Significant Decrease in Short Interest | 12/16/2024 |
5 | Abbott Laboratories Unveils Groundbreaking Leadless Pacemaker Technology | 12/17/2024 |
6 | Gryphon Investors Completes Successful Sale of Kano Laboratories | 12/18/2024 |
7 | IDEXX Laboratories earnings growth rate lags the 9.3 percent CAGR delivered to shareholders | 12/19/2024 |
8 | Jim Cramer on IDEXX Laboratories Is This Pet Stock Poised for a Comeback | 12/20/2024 |
| Begin Period Cash Flow | 5.8 B |
RDY |
Dr Reddys Relative Risk vs. Return Landscape
If you would invest 1,590 in Dr Reddys Laboratories on September 24, 2024 and sell it today you would lose (53.00) from holding Dr Reddys Laboratories or give up 3.33% of portfolio value over 90 days. Dr Reddys Laboratories is generating negative expected returns assuming volatility of 1.3911% on return distribution over 90 days investment horizon. In other words, 12% of stocks are less volatile than RDY, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Dr Reddys Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dr Reddys' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dr Reddys Laboratories, and traders can use it to determine the average amount a Dr Reddys' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0312
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RDY |
Estimated Market Risk
| 1.39 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dr Reddys is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dr Reddys by adding Dr Reddys to a well-diversified portfolio.
Dr Reddys Fundamentals Growth
RDY Stock prices reflect investors' perceptions of the future prospects and financial health of Dr Reddys, and Dr Reddys fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RDY Stock performance.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 13 B | ||||
| Shares Outstanding | 833.08 M | ||||
| Price To Earning | 31.58 X | ||||
| Price To Book | 3.56 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 279.16 B | ||||
| Gross Profit | 113.84 B | ||||
| EBITDA | 88.42 B | ||||
| Net Income | 55.68 B | ||||
| Cash And Equivalents | 2.93 B | ||||
| Cash Per Share | 208.58 X | ||||
| Total Debt | 20.02 B | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 366.54 X | ||||
| Cash Flow From Operations | 45.43 B | ||||
| Earnings Per Share | 0.78 X | ||||
| Market Capitalization | 13.11 B | ||||
| Total Asset | 387.52 B | ||||
| Retained Earnings | 265.26 B | ||||
| Working Capital | 152.01 B | ||||
| Current Asset | 1.81 B | ||||
| Current Liabilities | 976 M | ||||
About Dr Reddys Performance
Evaluating Dr Reddys' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Dr Reddys has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dr Reddys has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 200.74 | 167.78 | |
| Return On Tangible Assets | 0.16 | 0.11 | |
| Return On Capital Employed | 0.23 | 0.24 | |
| Return On Assets | 0.14 | 0.15 | |
| Return On Equity | 0.20 | 0.10 |
Things to note about Dr Reddys Laboratories performance evaluation
Checking the ongoing alerts about Dr Reddys for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dr Reddys Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dr Reddys generated a negative expected return over the last 90 days | |
| Latest headline from insidermonkey.com: Jim Cramer on IDEXX Laboratories Is This Pet Stock Poised for a Comeback |
- Analyzing Dr Reddys' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dr Reddys' stock is overvalued or undervalued compared to its peers.
- Examining Dr Reddys' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dr Reddys' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dr Reddys' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dr Reddys' stock. These opinions can provide insight into Dr Reddys' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.